NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
19 hedge funds and large institutions have $696K invested in NRX Pharmaceuticals Warrant in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
13% more capital invested
Capital invested by funds: $616K → $696K (+$80.1K)
12% more funds holding
Funds holding: 17 → 19 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$33.2K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$30.9K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$17.9K |
| 4 |
CI
Cowen Inc
New York
|
+$11.9K |
| 5 |
GCL
Glazer Capital LLC
New York
|
+$3.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$22K |
| 2 |
BCM
Bluefin Capital Management
New York
|
-$18K |
| 3 |
LIM
Longfellow Investment Management
Boston,
Massachusetts
|
-$8K |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$1.42K |
NRXPW Hedge Fund Activity: Q2 2019 in Review
19 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q2 2019, worth a combined $696K — up 13% from $616K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NRXPW positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $33.2K. The largest seller was Westchester Capital Management (New York), exiting entirely with an estimated $22K sold.
- 19 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q2 2019, up from 17 in Q1 2019.
- Funds reported $696K of NRX Pharmaceuticals Warrant stock for Q2 2019, up 13% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals Warrant positions in Q2 2019 and 2 closed out, a net change of +2 holders.
- The largest NRX Pharmaceuticals Warrant buyer in Q2 2019 was Hudson Bay Capital Management, an estimated $33.2K added.
- The largest NRX Pharmaceuticals Warrant seller in Q2 2019 was Westchester Capital Management (New York), an estimated $22K sold.
Based on aggregated 13F filings for Q2 2019.